Targeted Therapeutics, LLC. is a preclinical biopharmaceutical company developing novel therapeutics that target cancer cells by disrupting multiple signaling pathways that cancer cells depend on for survival.
Conventional targeted cancer therapies fail due to complex signaling loops that can compensate for the inhibition of a particular signaling pathway. With a combination of drugs, Targeted Therapeutics, LLC. is able to block survival signaling at multiple levels, induce mitosis-related cell death in proliferating cells and block mitotic entry in healthy cells leaving them unaffected.
Targeted Therapeutics, LLC. holds the patent on the method and pharmaceutical composition of its new class of drugs and unique approach to inhibiting and killing cancer cells.